Toni Choueiri
#47,383
Most Influential Person Now
American medical oncologist
Toni Choueiri's AcademicInfluence.com Rankings
Toni Choueirimedical Degrees
Medical
#621
World Rank
#830
Historical Rank
Oncology
#24
World Rank
#25
Historical Rank
Download Badge
Medical
Why Is Toni Choueiri Influential?
(Suggest an Edit or Addition)According to Wikipedia, Toni K. Choueiri is a Lebanese American medical oncologist and researcher. He is the Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School and Director of the Lank Center for Genitourinary Oncology at the Dana–Farber Cancer Institute. His work has led to the establishment of several novel drugs and prognostic factors in advanced renal cell carcinoma . Choueiri also co-established the International metastatic database Consortium with Daniel Heng. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.
Toni Choueiri's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- The Immune Landscape of Cancer (2018) (2766)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma (2017) (2186)
- Post-acute COVID-19 syndrome (2021) (2173)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) (1682)
- Pazopanib versus sunitinib in metastatic renal-cell carcinoma. (2013) (1590)
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) (1425)
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) (1264)
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (934)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma (2018) (772)
- Marital status and survival in patients with cancer. (2013) (757)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. (2013) (723)
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (2016) (703)
- The somatic genomic landscape of chromophobe renal cell carcinoma. (2014) (646)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019) (611)
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. (2021) (566)
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. (2017) (539)
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. (2021) (533)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial (2016) (477)
- Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (474)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
- Systemic Therapy for Metastatic Renal-Cell Carcinoma. (2017) (460)
- Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (433)
- Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. (2011) (411)
- Featured Updates to the NCCN Guidelines (2019) (401)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. (2013) (394)
- Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. (2010) (382)
- Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2014) (379)
- Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. (2014) (365)
- A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. (2017) (361)
- A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis (2019) (356)
- Exercise, free radicals and oxidative stress. (2001) (353)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
- Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. (2010) (335)
- The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. (2011) (328)
- Cost implications of the rapid adoption of newer technologies for treating prostate cancer. (2011) (326)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (324)
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients (2017) (322)
- Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. (2008) (313)
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. (2016) (295)
- The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. (2015) (286)
- NCCN clinical practice guidelines in oncology: kidney cancer. (2009) (286)
- Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. (2016) (284)
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. (2018) (273)
- A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma (2014) (269)
- Congestive heart failure risk in patients with breast cancer treated with bevacizumab. (2011) (268)
- Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR (2006) (267)
- Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
- Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. (2016) (261)
- Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. (2017) (261)
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update (2018) (258)
- Landscape of tumor-infiltrating T cell repertoire of human cancers (2016) (250)
- PD-L1 expression in nonclear-cell renal cell carcinoma. (2014) (246)
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. (2015) (244)
- Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up (2019) (244)
- Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (241)
- Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. (2016) (241)
- Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. (2009) (240)
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma (2015) (239)
- Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. (2015) (238)
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020) (234)
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma (2020) (231)
- Clinical factors associated with outcome in patients with metastatic clear‐cell renal cell carcinoma treated with vascular endothelial growth factor‐targeted therapy (2007) (225)
- Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. (2014) (222)
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. (2021) (222)
- ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. (2014) (219)
- A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. (2014) (211)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial (2014) (208)
- Lack of reduction in racial disparities in cancer‐specific mortality over a 20‐year period (2014) (205)
- Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology (2019) (202)
- Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. (2014) (202)
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. (2018) (201)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma. (2017) (194)
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial (2020) (192)
- Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines (2015) (186)
- Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma (2018) (185)
- Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria (2013) (182)
- Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era. (2014) (180)
- Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium (2021) (178)
- NCCN clinical practice guidelines in oncology: testicular cancer. (2009) (173)
- Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. (2012) (171)
- Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group (2011) (170)
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2016) (169)
- Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. (2016) (169)
- Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. (2012) (168)
- Targeting the HIF2–VEGF axis in renal cell carcinoma (2020) (167)
- COVID-19 and Cancer: Current Challenges and Perspectives (2020) (160)
- von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. (2008) (159)
- Comparative analysis of outcomes and costs following open radical cystectomy versus robot-assisted laparoscopic radical cystectomy: results from the US Nationwide Inpatient Sample. (2012) (157)
- Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. (2011) (155)
- Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. (2012) (154)
- Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway (2015) (153)
- Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. (2013) (152)
- Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. (2016) (148)
- Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. (2011) (148)
- Pazopanib: Clinical development of a potent anti-angiogenic drug. (2011) (145)
- Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. (2019) (143)
- Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma (2021) (142)
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. (2019) (138)
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer. (2014) (137)
- Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. (2016) (135)
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. (2020) (134)
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2019) (130)
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
- Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. (2021) (129)
- A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. (2015) (129)
- Sunitinib rechallenge in metastatic renal cell carcinoma patients (2010) (128)
- ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. (2011) (127)
- Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology (2017) (126)
- Cancer Screening Tests and Cancer Diagnoses During the COVID-19 Pandemic. (2021) (125)
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. (2017) (124)
- NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. (2019) (122)
- Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy (2009) (121)
- Kidney cancer, version 3.2015. (2015) (119)
- Prostate-Specific Antigen Screening After 2012 US Preventive Services Task Force Recommendations. (2015) (118)
- Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19 (2021) (117)
- Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial (2017) (117)
- Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. (2011) (117)
- Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma (2010) (115)
- Cancer-specific outcomes among young adults without health insurance. (2014) (115)
- Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. (2011) (115)
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. (2013) (112)
- A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. (2008) (112)
- Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. (2016) (111)
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. (2012) (111)
- Novel Roles of c-Met in the Survival of Renal Cancer Cells through the Regulation of HO-1 and PD-L1 Expression* (2015) (110)
- Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes (2020) (109)
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors (2014) (109)
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma (2020) (109)
- Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma (2021) (109)
- Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study (2020) (107)
- Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. (2015) (107)
- Prostate cancer reactivates developmental epigenomic programs during metastatic progression (2020) (106)
- Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors (2010) (105)
- Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
- Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. (2019) (102)
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors. (2014) (100)
- Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. (2018) (100)
- Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. (2018) (99)
- Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma (2015) (99)
- Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. (2013) (99)
- The Immune Landscape of Cancer. (2019) (99)
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. (2017) (98)
- An overview of targeted treatments in cancer. (2003) (97)
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (97)
- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. (2022) (96)
- Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. (2017) (94)
- Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. (2014) (94)
- Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. (2017) (94)
- Loss of Breast Cancer Metastasis Suppressor 1 Protein Expression Predicts Reduced Disease-Free Survival in Subsets of Breast Cancer Patients (2006) (94)
- Randomized, Open-Label, Phase III Trial Of Pazopanib Versus Sunitinib In First-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma (MRCC): Results of the Comparz Trial (2012) (94)
- BRAF mutations in metanephric adenoma of the kidney. (2012) (93)
- Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome. (2012) (93)
- Thermal ablation vs surgery for localized kidney cancer: a Surveillance, Epidemiology, and End Results (SEER) database analysis. (2011) (92)
- Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy (2010) (91)
- Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer. (2016) (91)
- CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (2017) (90)
- COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials (2021) (90)
- Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. (2018) (89)
- 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial (2020) (89)
- Testicular cancer, version 2.2015: Clinical pactice guidelines in oncology (2015) (88)
- Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. (2016) (87)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
- Genome-wide association study identifies multiple risk loci for renal cell carcinoma (2017) (86)
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. (2019) (84)
- Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). (2019) (84)
- Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. (2011) (84)
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma (2018) (83)
- Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. (2016) (82)
- Progression‐free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy (2011) (81)
- FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (81)
- Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. (2019) (81)
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. (2020) (80)
- Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma (2020) (79)
- Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2015) (79)
- Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. (2018) (78)
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma (2013) (78)
- Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. (2018) (77)
- Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. (2014) (77)
- Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. (2014) (77)
- Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment (2016) (76)
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study (2015) (76)
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. (2019) (76)
- Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. (2010) (75)
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer (2019) (75)
- Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. (2018) (74)
- Analgesic use and the risk of kidney cancer: A meta‐analysis of epidemiologic studies (2014) (74)
- Strategies to design clinical studies to identify predictive biomarkers in cancer research. (2017) (74)
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. (2015) (74)
- The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. (2014) (74)
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma (2015) (74)
- Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites (2018) (73)
- Kidney cancer, version 2.2014. (2014) (73)
- Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. (2015) (72)
- Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction. (2012) (72)
- Association of androgen‐deprivation therapy with excess cardiac‐specific mortality in men with prostate cancer (2015) (72)
- Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy. (2014) (72)
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
- Testicular Cancer, Version 2.2015. (2015) (69)
- Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. (2005) (69)
- First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. (2019) (68)
- Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma. (2014) (67)
- Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. (2013) (67)
- Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium. (2013) (67)
- Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. (2015) (65)
- Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. (2016) (65)
- Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. (2017) (65)
- Prospective evaluation of analgesic use and risk of renal cell cancer. (2011) (64)
- Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2017) (64)
- Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta‐Analysis (2018) (64)
- IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
- Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival (2021) (63)
- Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. (2014) (63)
- Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials (2017) (63)
- Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. (2015) (62)
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial (2019) (62)
- First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2016) (61)
- Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. (2008) (61)
- Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma (RCC) (2014) (60)
- Evolving Systemic Treatment Landscape for Patients With Advanced Renal Cell Carcinoma. (2018) (60)
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (2018) (60)
- Metabolic complications with the use of mTOR inhibitors for cancer therapy. (2014) (59)
- Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review (2010) (59)
- Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. (2007) (59)
- Income inequality and treatment of African American men with high-risk prostate cancer. (2015) (58)
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (2020) (58)
- IL-8 and cancer prognosis on immunotherapy (2020) (58)
- Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? (2012) (58)
- Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups (2016) (57)
- Refusal of curative radiation therapy and surgery among patients with cancer. (2014) (57)
- Mental health outcomes in elderly men with prostate cancer. (2014) (57)
- Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials. (2013) (57)
- Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. (2016) (56)
- Comparative effectiveness of robot-assisted vs. open radical cystectomy. (2017) (56)
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). (2013) (56)
- The influence of marital status on the use of breast, cervical, and colorectal cancer screening. (2016) (55)
- The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act (2014) (55)
- Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. (2016) (55)
- A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC) (2007) (55)
- From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
- Kidney cancer, version 1.2021: Featured updates to the nccn guidelines (2020) (55)
- Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma. (2006) (54)
- Elicitation of health state utilities in metastatic renal cell carcinoma (2010) (54)
- Erratum: Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma (Cancer Cell (2016) 29(5) (723–736) (S153561081630160X) (10.1016/j.ccell.2016.04.002)) (2016) (54)
- Phase II study of lenalidomide in patients with metastatic renal cell carcinoma (2006) (54)
- Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. (2013) (53)
- NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. (2011) (53)
- Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer (2012) (53)
- Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy (2017) (53)
- Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. (2011) (52)
- Patterns of care for radical prostatectomy in the United States from 2003 to 2005. (2008) (52)
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer (2018) (52)
- Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. (2017) (52)
- Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy (2011) (52)
- Adrenocortical carcinoma: the management of metastatic disease. (2014) (52)
- Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. (2018) (51)
- The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study (2019) (51)
- Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma (2013) (51)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. (2015) (50)
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. (2020) (49)
- Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (2018) (49)
- Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma. (2020) (49)
- Kidney Cancer (2016) (48)
- Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma (2014) (48)
- Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9? (2016) (47)
- 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. (2014) (46)
- Chemotherapy for muscle-invasive bladder cancer treated with definitive radiotherapy: persisting uncertainties (2008) (46)
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events (2018) (46)
- The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients (2013) (46)
- Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. (2014) (46)
- Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma (2015) (46)
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. (2015) (45)
- Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma (2016) (45)
- Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). (2020) (45)
- Risk of bilateral renal cell cancer. (2009) (45)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation (2016) (44)
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma (2022) (44)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data (2017) (44)
- Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma (2020) (44)
- Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders (2018) (43)
- The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. (2018) (43)
- Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. (2017) (43)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (43)
- Pan-urologic cancer genomic subtypes that transcend tissue of origin (2017) (43)
- Racial Disparity in Delivering Definitive Therapy for Intermediate/High-risk Localized Prostate Cancer: The Impact of Facility Features and Socioeconomic Characteristics. (2017) (43)
- Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. (2017) (42)
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma (2018) (42)
- Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer (2013) (42)
- The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: A Retrospective Immunohistochemical Study (2007) (42)
- Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis. (2017) (41)
- Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients (2013) (41)
- First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. (2017) (41)
- PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN (2019) (40)
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study (2018) (40)
- Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. (2006) (40)
- Suicide and accidental deaths among patients with non‐metastatic prostate cancer (2016) (40)
- Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma (2019) (40)
- Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER. (2021) (40)
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. (2020) (40)
- Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis (2011) (40)
- Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study (2020) (39)
- The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. (2006) (39)
- JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). (2018) (39)
- Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: Implications for alternative response criteria (2014) (39)
- [Breast cancer in the early stage]. (2012) (39)
- RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2014) (39)
- Haematologic toxicities associated with the addition of bevacizumab in cancer patients. (2011) (39)
- Sunitinib‐induced macrocytosis in patients with metastatic renal cell carcinoma (2008) (39)
- Statins and survival outcomes in patients with metastatic renal cell carcinoma. (2016) (38)
- Treatment selection for patients with metastatic renal cell carcinoma (2009) (38)
- Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors (2013) (38)
- Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. (2020) (38)
- Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. (2019) (38)
- Surgeon and Hospital Level Variation in the Costs of Robot-Assisted Radical Prostatectomy. (2016) (38)
- PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond (2014) (38)
- Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. (2015) (38)
- Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). (2012) (38)
- The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma. (2006) (38)
- Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors (2020) (38)
- Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. (2020) (38)
- Recognizing and Managing Left Ventricular Dysfunction Associated With Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway (2014) (38)
- Variation in the use of active surveillance for low‐risk prostate cancer (2018) (38)
- HER2 as a target in invasive urothelial carcinoma (2015) (37)
- Disparities in selective referral for cancer surgeries: implications for the current healthcare delivery system (2014) (37)
- Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies. (2015) (37)
- Role of aromatase inhibitors in the treatment of breast cancer. (2004) (37)
- Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. (2016) (37)
- Racial Disparities in End-of-Life Care Among Patients With Prostate Cancer: A Population-Based Study. (2015) (37)
- Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma. (2017) (36)
- Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). (2017) (36)
- Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States. (2015) (36)
- Characterizing the outcomes of metastatic papillary renal cell carcinoma (2017) (36)
- Comparative effectiveness, costs and trends in treatment of small renal masses from 2005 to 2007 (2013) (35)
- A nomogram including baseline prognostic factors to estimate the activity of second‐line therapy for advanced urothelial carcinoma (2014) (35)
- Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients. (2012) (35)
- Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. (2017) (35)
- Vinflunine: drug safety evaluation of this novel synthetic vinca alkaloid (2011) (35)
- Impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death (2010) (35)
- Determinants of performing radical prostatectomy pelvic lymph node dissection and the number of lymph nodes removed in elderly men. (2011) (35)
- Recommendations for the Management of Rare Kidney Cancers. (2017) (35)
- An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications (2008) (35)
- Biomarkers: the next therapeutic hurdle in metastatic renal cell carcinoma (2012) (34)
- Pancreatitis with vascular endothelial growth factor receptor tyrosine kinase inhibitors. (2014) (34)
- Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions. (2011) (34)
- Contemporary national trends in prostate cancer risk profile at diagnosis (2019) (34)
- Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. (2018) (34)
- Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. (2019) (34)
- Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer. (2014) (34)
- High Throughput Kinomic Profiling of Human Clear Cell Renal Cell Carcinoma Identifies Kinase Activity Dependent Molecular Subtypes (2015) (34)
- Morbidity and Mortality of Locally Advanced Prostate Cancer: A Population Based Analysis Comparing Radical Prostatectomy versus External Beam Radiation (2017) (34)
- Evaluation of disease‐free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial‐level meta‐analysis (2018) (34)
- Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. (2013) (34)
- Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma (2017) (33)
- Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer (2020) (33)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (33)
- Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study (2021) (33)
- Non-Clear Cell Renal Cell Carcinomas: From Shadow to Light. (2018) (32)
- Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. (2021) (32)
- Response of renal cell carcinoma pancreatic metastasis to sunitinib treatment: a retrospective analysis. (2007) (32)
- Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. (2015) (32)
- The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer (2020) (32)
- Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. (2012) (32)
- Hepatotoxicity with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A meta-analysis of randomized clinical trials. (2015) (32)
- Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1 (2019) (32)
- A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. (2009) (32)
- Asian Americans and prostate cancer: A nationwide population-based analysis. (2016) (32)
- Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results (2016) (32)
- Non-clear cell renal cancer: features and medical management. (2009) (32)
- Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma (2020) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma (2015) (31)
- Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
- The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients (2012) (30)
- Management of clinical stage I nonseminomatous germ cell testicular cancer. (2007) (29)
- Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. (2014) (29)
- ABO blood group and risk of renal cell cancer. (2012) (29)
- A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. (2014) (29)
- HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study (2021) (29)
- Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. (2011) (29)
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? (2019) (29)
- Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
- Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy. (2018) (28)
- Radiogenomics in renal cell carcinoma (2019) (28)
- PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. (2014) (28)
- Determinants of cancer screening in Asian-Americans (2016) (28)
- Recent advances in the systemic treatment of metastatic papillary renal cancer (2009) (28)
- Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. (2022) (28)
- Association Between Older Age and Increasing Gleason Score. (2015) (28)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. (2021) (28)
- Geographic Distribution of Racial Differences in Prostate Cancer Mortality (2020) (28)
- Metabolic reprogramming in renal cancer: Events of a metabolic disease. (2021) (28)
- A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy (2014) (28)
- Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). (2020) (28)
- Androgen‐suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke (2010) (28)
- The burden of skeletal-related events in patients with prostate cancer and bone metastasis. (2015) (27)
- Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). (2020) (27)
- Testicular cancer. (2012) (27)
- Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies (2020) (27)
- Statin use and the risk of renal cell carcinoma in 2 prospective US cohorts (2012) (27)
- Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--implications for a risk-adapted follow-up strategy. (2010) (27)
- Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. (2014) (27)
- Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma (2020) (27)
- Rethinking Clinical Trials Reform During the COVID-19 Pandemic. (2020) (27)
- Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials (2017) (27)
- Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era. (2016) (27)
- Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. (2016) (26)
- Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 (2019) (26)
- Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. (2008) (26)
- Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. (2015) (26)
- Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy. (2017) (26)
- Phenoxodiol: Isoflavone analog with antineoplastic activity (2006) (26)
- Posttreatment prostate specific antigen nadir predicts prostate cancer specific and all cause mortality. (2012) (25)
- Differential expression of caveolin‐1 in renal neoplasms (2007) (25)
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study. (2020) (25)
- A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). (2018) (25)
- Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. (2021) (25)
- Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. (2013) (25)
- ClearCode 34 : A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma (2014) (25)
- Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF) -targeted therapy in metastatic renal cell carcinoma (RCC) (2007) (25)
- Differential Expression of PD‐L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications (2017) (25)
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma (2018) (25)
- Future directions and targeted therapies in bladder cancer. (2015) (25)
- Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (2012) (25)
- Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals (2019) (25)
- Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma (2015) (25)
- Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer (2022) (25)
- Liver Disease in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer (2018) (25)
- Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). (2015) (25)
- Risk factors and model for predicting toxicity‐related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (2016) (24)
- The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy (2012) (24)
- Hypothyroidism During Tyrosine Kinase Inhibitor Therapy Is Associated with Longer Survival in Patients with Advanced Nonthyroidal Cancers. (2018) (24)
- Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. (2018) (24)
- Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. (2014) (24)
- Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population. (2014) (24)
- CDKN2A Alterations and Response to Immunotherapy in Solid Tumors (2021) (24)
- Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma. (2020) (24)
- Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial (2021) (24)
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) (2018) (24)
- The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. (2010) (24)
- Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. (2019) (24)
- Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma (2022) (24)
- Treatment outcome for metastatic papillary and chromophobe renal cell carcinoma (RCC) patients treated with tyrosine-kinase inhibitors (TKIs) sunitinib and sorafenib (2007) (24)
- FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC). (2020) (24)
- Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial (2019) (24)
- Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma. (2021) (23)
- PD-L 1 expression in nonclear-cell renal cell carcinoma (2014) (23)
- Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. (2021) (23)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy (2012) (23)
- Risk Factors for New Hypothyroidism During Tyrosine Kinase Inhibitor Therapy in Advanced Nonthyroidal Cancer Patients. (2018) (23)
- National sociodemographic disparities in the treatment of high‐risk prostate cancer: Do academic cancer centers perform better than community cancer centers? (2016) (23)
- NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE‐INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY: MP34‐11 (2017) (23)
- LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis (2020) (23)
- Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). (2020) (23)
- Risk of prostate cancer mortality in men with a history of prior cancer (2016) (23)
- Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2019) (23)
- Association Between Androgen Deprivation Therapy and Mortality Among Patients With Prostate Cancer and COVID-19 (2021) (23)
- RECIST 1.1 compared with RECIST 1.0 in patients with advanced renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. (2015) (22)
- Who bears the greatest burden of aggressive treatment of indolent prostate cancer? (2015) (22)
- Soluble PD-L1 as an early marker of progressive disease on nivolumab (2022) (22)
- Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2019) (22)
- Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer (2021) (22)
- Recent advances in immunotherapy for the treatment of prostate cancer (2011) (22)
- RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse (2021) (22)
- Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas (2018) (22)
- Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis* (2009) (21)
- Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). (2019) (21)
- A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (21)
- Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. (2015) (21)
- Factors associated with the adoption of minimally invasive radical prostatectomy in the United States. (2012) (21)
- PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704). (2019) (21)
- A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. (2020) (21)
- Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study. (2020) (21)
- Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial. (20)
- An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (2018) (20)
- Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma (2017) (20)
- Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. (2018) (20)
- Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. (2021) (20)
- Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. (2013) (20)
- Occult High-risk Disease in Clinically Low-risk Prostate Cancer with ≥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk? (2016) (20)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression (2017) (20)
- Evolving role of pegylated interferons in metastatic renal cell carcinoma (2003) (20)
- Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (20)
- Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer (2018) (20)
- A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer (2019) (20)
- Endothelin receptor antagonists: Rationale, clinical development, and role in prostate cancer therapeutics (2006) (19)
- ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma (2021) (19)
- Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). (2018) (19)
- Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor–Targeting Therapy in Advanced Renal Cell Carcinoma with Bone Metastases (2018) (19)
- Expression of Ror2 Mediates Invasive Phenotypes in Renal Cell Carcinoma (2014) (19)
- A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance (2020) (19)
- Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). (2020) (19)
- VEGF inhibitors in metastatic renal cell carcinoma: current therapies and future perspective. (2011) (19)
- Sex specific associations in genome wide association analysis of renal cell carcinoma (2019) (19)
- CABOzantinib versus SUNitinib (CABOSUN) as initial targeted therapy for patients with metastatic renal cell carcinoma (mRCC) of poor and intermediate risk groups: Results from ALLIANCE A031203 trial (2016) (19)
- Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (2019) (19)
- PD-L1 expression in non-clear cell renal cell carcinoma. (2014) (19)
- Convalescent Plasma and Improved Survival in Patients with Hematologic Malignancies and COVID-19 (2021) (19)
- Use of surveillance imaging following treatment of small renal masses. (2013) (19)
- Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). (2021) (19)
- Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. (2018) (19)
- Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101). (2017) (19)
- The role of site-specific therapy for cancers of unknown of primary: A meta-analysis. (2020) (19)
- The impact of Medicare eligibility on cancer screening behaviors. (2016) (18)
- Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2020) (18)
- Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19). (2020) (18)
- Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2016) (18)
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series (2017) (18)
- MET as a Target in Papillary Renal Cell Carcinoma (2014) (18)
- Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma (2016) (18)
- 702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study (2020) (18)
- The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. (2018) (18)
- Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC). (2018) (18)
- The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. (2019) (18)
- Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status (2018) (18)
- Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (2017) (18)
- Precision medicine for metastatic renal cell carcinoma. (2014) (18)
- First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. (2021) (18)
- The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. (2021) (17)
- Non-clear cell renal cell carcinoma, part 2: therapy. (2015) (17)
- Burden of hospital admissions and utilization of hospice care in metastatic prostate cancer patients. (2015) (17)
- Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. (2017) (17)
- Somatic Copy Number Abnormalities and Mutations in PI3K/AKT/mTOR Pathway Have Prognostic Significance for Overall Survival in Platinum Treated Locally Advanced or Metastatic Urothelial Tumors (2015) (17)
- Clinical treatment decisions for advanced renal cell cancer. (2013) (17)
- A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study. (2010) (17)
- A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. (2012) (16)
- A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) (16)
- Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race‐based differences in survival? (2019) (16)
- Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years. (2015) (16)
- ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: A systematic review and meta-analysis. (2017) (16)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (2012) (16)
- Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. (2019) (16)
- CONTACT-03: Randomized, open-label phase III study of atezolizumab plus cabozantinib versus cabozantinib monotherapy following progression on/after immune checkpoint inhibitor (ICI) treatment in patients with advanced/metastatic renal cell carcinoma. (2021) (16)
- NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. (2014) (16)
- Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle‐invasive Urinary Bladder Cancer (2017) (15)
- Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma. (2016) (15)
- RET protein expression in papillary renal cell carcinoma. (2012) (15)
- Immunotherapy in the Elderly. (2017) (15)
- Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). (2019) (15)
- Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (15)
- Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). (2016) (15)
- Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes (2020) (15)
- Weight gain on androgen deprivation therapy: which patients are at highest risk? (2014) (15)
- Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer (2014) (15)
- Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564. (2022) (15)
- Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis (2014) (15)
- A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies (2016) (15)
- Genomic investigation of etiologic heterogeneity: methodologic challenges (2014) (15)
- Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. (2016) (15)
- Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC (2021) (15)
- Acquired Activated Protein C Resistance in Myeloma Patients with Venous Thromboembolic Events (2003) (15)
- Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy (2018) (14)
- Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. (2022) (14)
- Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. (2021) (14)
- Risk of dementia following androgen deprivation therapy for treatment of prostate cancer (2019) (14)
- Non-clear cell renal cell carcinoma, part 1: histology. (2015) (14)
- KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer. (2015) (14)
- Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic (2021) (14)
- ABO blood group alleles and prostate cancer risk: Results from the breast and prostate cancer cohort consortium (BPC3) (2015) (14)
- PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). (2019) (14)
- Sunitinib-induced pseudoprogression after whole-brain radiotherapy for metastatic renal cell carcinoma. (2010) (14)
- Metabolomic correlates of response in nivolumab-treated renal cell carcinoma and melanoma patients. (2017) (14)
- Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. (2022) (14)
- Impact of body composition on clinical outcomes in metastatic renal cell cancer. (2011) (13)
- Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. (2020) (13)
- Safety of VEGF-targeted tyrosine kinase inhibitors in patients (Pts) with metastatic renal cell carcinoma (mRCC) and central nervous system (CNS) metastases (2007) (13)
- Incidence of Severe Nephrotoxicity With Cisplatin Based on Renal Function Eligibility Criteria: Indirect Comparison Meta-analysis (2016) (13)
- Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study. (2019) (13)
- Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. (2016) (13)
- Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. (2016) (13)
- Optimizing recent advances in metastatic renal cell carcinoma (2009) (13)
- Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). (2012) (13)
- Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. (2017) (13)
- Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion. (2017) (13)
- Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. (2015) (13)
- Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). (2021) (13)
- Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. (2012) (13)
- Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial (2022) (13)
- Recent progress and pitfalls in testing novel agents in castration-resistant prostate cancer. (2009) (13)
- Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis. (2020) (13)
- Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. (2016) (13)
- Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. (2019) (13)
- A Randomized Phase II Study of AGS-16C3F Versus Axitinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma. (2020) (13)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma. (2014) (13)
- Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era (2018) (13)
- Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial. (2021) (13)
- Integrative clinical and molecular characterization of translocation renal cell carcinoma. (2022) (13)
- LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19) (2020) (13)
- Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial (2021) (13)
- Analysis of Response Data for Assessing Treatment Effects in Comparative Clinical Studies (2020) (12)
- Re: Fabio Conforti, Laura Pala, Vincenzo Bagnardi, et al. Cancer Immunotherapy Efficacy and Patients' Sex: A Systematic Review and Meta-analysis. Lancet Oncol 2018;19:737-46: Outcomes of Metastatic Renal Cell Carcinoma by Gender: Contrasting Results from the International mRCC Database Consortium. (2018) (12)
- The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine (2013) (12)
- Care without a compass: Including patients with cancer in COVID-19 studies (2021) (12)
- KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma. (2018) (12)
- Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). (2018) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- 7108 Phase II study of IMC-1121B in patients with metastatic renal cell carcinoma (mRCC) following failure of VEGFR-2 tyrosine kinase inhibitor (TKI) therapy: interim results (IMCL CP12–0605/NCT00515697) (2009) (12)
- Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design. (2015) (12)
- Discontinuing VEGF‐targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second‐line Therapies in Metastatic Renal Cell Carcinoma (2017) (12)
- Utilization and expense of adjuvant cancer therapies following radical prostatectomy (2011) (12)
- Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. (2015) (12)
- Next Steps: Sequencing Therapies in Metastatic Kidney Cancer in the Contemporary Era. (2021) (12)
- Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma (2020) (12)
- Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. (2018) (12)
- Doxil (D), Vincristine (V), Reduced Frequency Dexamethasone (d) and Revlimid(R) (DVd-R) Results in a High Response Rate in Patients with Refractory Multiple Myeloma (RMM). (2005) (12)
- Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). (2017) (12)
- Everolimus- and temsirolimus-associated enteritis: report of three cases. (2011) (12)
- 660P Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update (2021) (12)
- Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC) (2019) (12)
- First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. (2014) (12)
- Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2014) (12)
- A phase III trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab vs sunitinib alone in first-line treatment of patients (Pts) with metastatic renal cell carcinoma (RCC). (2017) (12)
- A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma. (2014) (12)
- Comorbidity, body mass index, and age and the risk of nonprostate‐cancer‐specific mortality after a postradiation prostate‐specific antigen recurrence (2010) (12)
- Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors. (2022) (12)
- A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). (2017) (12)
- Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer (2016) (12)
- A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC (2019) (12)
- Antibiotic use and outcomes with systemic therapy in metastatic renal cell carcinoma (mRCC). (2018) (12)
- Mutation burden and tumor neoantigens in RCC patients (pts) treated with nivolumab. (2016) (12)
- Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma (2020) (11)
- Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. (2010) (11)
- Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. (2015) (11)
- Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2018) (11)
- Variation in Positive Surgical Margin Status After Radical Prostatectomy for pT2 Prostate Cancer. (2019) (11)
- Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma. (2022) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma (2018) (11)
- Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. (2021) (11)
- Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (2021) (11)
- Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity. (2014) (11)
- Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors (2021) (11)
- Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC). (2018) (11)
- The Use of Prostate Specific Antigen Screening in Purchased versus Direct Care Settings: Data from the TRICARE® Military Database (2017) (11)
- Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC) (2017) (11)
- Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC). (2016) (11)
- Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. (2011) (11)
- LBA38Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) (2017) (11)
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. (2018) (11)
- Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC). (2021) (11)
- Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial. (2018) (11)
- Contemporary nationwide patterns of self-reported prostate-specific antigen screening in US veterans. (2015) (11)
- KEYNOTE-057: Phase 2 study of pembrolizumab for patients (pts) with Bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). (2016) (11)
- Novel Therapeutic Approaches and the Evolution of Drug Development in Advanced Kidney Cancer. (2020) (11)
- Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. (2016) (11)
- Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with renal cell carcinoma (RCC) and other malignancies: A meta-analysis of randomized clinical trials. (2015) (10)
- Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. (2017) (10)
- Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls. (2011) (10)
- Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC). (2019) (10)
- Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. (2016) (10)
- Clinical activity and safety of antiprogrammed death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in patients (pts) with previously treated, metastatic renal cell carcinoma (mRCC): An updated analysis. (2013) (10)
- A single-arm biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer (PRCC). (2017) (10)
- Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy (2016) (10)
- Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2019) (10)
- Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC). (2014) (10)
- Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma (2019) (10)
- Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. (2021) (10)
- A phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor-risk. (2020) (10)
- Phase II study of nivolumab and ipilimumab for advanced bladder cancer of variant histologies (BCVH). (2019) (10)
- Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. (2014) (10)
- The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases (2017) (10)
- Identification of ALK Gene Alterations in Urothelial Carcinoma (2014) (10)
- Association of circulating tumor DNA (ctDNA) detection in metastatic renal cell carcinoma (mRCC) with tumor burden. (2017) (10)
- Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) (2020) (10)
- Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (10)
- The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy. (2020) (10)
- Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis (2017) (10)
- Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. (2022) (10)
- Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study. (2016) (10)
- KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy. (2015) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Kidney cancer: Recurrence in renal cell carcinoma: the work is not done (2016) (10)
- ABO blood group and risk of renal cell cancer. (2012) (10)
- Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC) (2020) (10)
- Metastatic renal cell carcinoma: Contending with a sea change in therapy. (2015) (10)
- Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. (2016) (10)
- A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). (2012) (9)
- Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC). (2011) (9)
- Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective. (2015) (9)
- Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors (2020) (9)
- Patient-reported outcomes of patients with advanced renal cell carcinoma (aRCC) treated with first-line nivolumab plus cabozantinib versus sunitinib: The CheckMate 9ER trial. (2021) (9)
- Treatment of Advanced Renal-Cell Carcinoma. (2016) (9)
- The evolving landscape of metastatic renal cell carcinoma. (2012) (9)
- CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer (2021) (9)
- The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT). (2014) (9)
- Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers. (2020) (9)
- Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. (2011) (9)
- Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma (2016) (9)
- Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). (2012) (9)
- Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). (2017) (9)
- 849PDComparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC) (2017) (9)
- Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) - an International mRCC Database Consortium (IMDC) analysis. (2021) (9)
- COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma (2019) (9)
- Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214 (2019) (9)
- Phase 1 dose-finding study of cabozantinib (cabo) plus abiraterone (abi) combination therapy in castration resistant prostate cancer (CRPC): An investigator-sponsored study. (2014) (9)
- Use of Preventive Health Services Among Cancer Survivors in the U.S. (2018) (9)
- Allelic imbalance reveals widespread germline-somatic regulatory differences and prioritizes risk loci in Renal Cell Carcinoma (2019) (9)
- Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium. (2015) (8)
- Review: Updates on novel therapies for metastatic renal cell carcinoma (2010) (8)
- An evaluation of the ‘weekend effect’ in patients admitted with metastatic prostate cancer (2015) (8)
- Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study). (2013) (8)
- A phase II biomarker assessment of tivozanib in oncology (BATON) trial in patients (pts) with advanced renal cell carcinoma (RCC). (2012) (8)
- Response of Primary Renal Cell Carcinoma to Systemic Therapy. (2019) (8)
- Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study (2021) (8)
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
- Trans-ethnic variation in germline variants of patients with renal cell carcinoma. (2021) (8)
- LBA24 Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study (2021) (8)
- Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures (2017) (8)
- Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma (2020) (8)
- Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. (2008) (8)
- Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. (2017) (8)
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. (2020) (8)
- Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. (2022) (8)
- Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. (2018) (8)
- Incidence and determinants of 1-month mortality after cancer-directed surgery. (2014) (8)
- The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium. (2014) (8)
- PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma. (2014) (8)
- Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2017) (8)
- 709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study (2020) (8)
- Renal-cell carcinoma: a step closer to a new classification. (2013) (8)
- Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome. (2011) (8)
- Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil (2017) (8)
- Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma (2021) (8)
- FGFR 3 expression in primary and metastatic urothelial carcinoma of the bladder (2014) (8)
- Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. (2021) (8)
- Active Smoking Is Associated With Worse Prognosis in Metastatic Renal Cell Carcinoma Patients Treated With Targeted Therapies (2019) (8)
- HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma (2018) (8)
- Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. (2022) (7)
- Temporal trends and predictors in the use of Stereotactic Body Radiotherapy for treatment of metastatic Renal Cell Carcinoma in the United States. (2021) (7)
- Differential Side Effects Profile in mCRPC Patients Treated With Abiraterone or Enzalutamide: A Meta-Analysis of Randomized Controlled Trials. (2016) (7)
- Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC). (2016) (7)
- Hematologic toxicities in cancer patients treated with the multityrosine kinase sorafenib: A meta-analysis of clinical trials. (2011) (7)
- Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) (2016) (7)
- Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC). (2016) (7)
- Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma (2020) (7)
- Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. (2019) (7)
- Renal cell carcinoma. (2011) (7)
- Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: Subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial. (2018) (7)
- Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). (2019) (7)
- Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results From the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. (2022) (7)
- Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? (2009) (7)
- Germline variants associated with toxicity to immune checkpoint blockade (2022) (7)
- Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101. (2020) (7)
- COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE) (2022) (7)
- Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model (2021) (7)
- Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. (2015) (7)
- Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2020) (7)
- Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160). (2017) (7)
- Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial (2021) (7)
- Disparities in the Receipt of Local Treatment of Node‐positive Prostate Cancer (2017) (7)
- Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis. (2013) (7)
- 1051PDIMMUNOMODULATORY ACTIVITY OF NIVOLUMAB IN PREVIOUSLY TREATED AND UNTREATED METASTATIC RENAL CELL CARCINOMA (MRCC): BIOMARKER-BASED RESULTS FROM A RANDOMIZED CLINICAL TRIAL. (2014) (7)
- Outcomes of first-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2021) (6)
- Evaluation of brain metastasis in JAVELIN Renal 101: Efficacy of avelumab + axitinib (A+Ax) versus sunitinib (S). (2020) (6)
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2019) (6)
- Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors. (2021) (6)
- Adjuvant versus neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC): Analysis of the National Cancer Database (NCDB). (2016) (6)
- Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045. (2017) (6)
- Quality-adjusted time without symptoms or toxicity (Q-TWiST): Analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203). (2018) (6)
- A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials. (2012) (6)
- Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer. (2013) (6)
- CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma. (2019) (6)
- Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. (2018) (6)
- Phase III study of the hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 versus everolimus in previously treated patients with advanced clear cell renal cell carcinoma (ccRCC). (2020) (6)
- Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? (2019) (6)
- Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset (2021) (6)
- Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR). (2014) (6)
- Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells (2021) (6)
- LBA37_PRPembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial (2017) (6)
- Risk Assessment in Small Renal Masses: A Review Article. (2017) (6)
- A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer. (2011) (6)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (6)
- Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study. (2021) (6)
- CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2022) (6)
- Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population. (2011) (6)
- cMet: Results in papillary renal cell carcinoma of a phase I study of AZD6094/volitinib leading to a phase 2 clinical trial with AZD6094/volitinib in patients with advanced papillary renal cell cancer (PRCC). (2015) (6)
- Hereditary hemorrhagic telangiectasia, idiopathic thrombocytopenic purpura, and chronic lymphocytic leukemia treated with rituximab. (2002) (6)
- Prevalence of Nonrecommended Screening for Prostate Cancer and Breast Cancer in the United States: A Nationwide Survey Analysis. (2016) (6)
- The Borealis-2 clinical trial: A randomized phase II study of OGX-427 plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer. (2013) (6)
- Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). (2019) (6)
- Clinical factors associated with outcome in metastatic renal cell carcinoma patients treated with VEGF-targeted therapy (2007) (6)
- Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC). (2016) (6)
- Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis. (2018) (6)
- Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (2018) (6)
- Efficacy and safety of avelumab plus axitinib (A + Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (6)
- Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. (2019) (6)
- A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC) (2016) (6)
- A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma. (2016) (5)
- Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study. (2021) (5)
- PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. (2014) (5)
- Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC). (2013) (5)
- Initial results of a phase II study of nivolumab and ipilimumab in metastatic adrenal tumours (2019) (5)
- Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC). (2021) (5)
- First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal cell carcinoma (mRCC): Preliminary results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2019) (5)
- Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101. (2021) (5)
- Why shouldn't we use warfarin alone to treat acute venous thrombosis? (2002) (5)
- Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC). (2018) (5)
- 924TiPSavolitinib versus sunitinib in patients with MET-driven, unresectable and locally advanced or metastatic papillary renal cell carcinoma: SAVOIR, a randomised, phase III trial (2017) (5)
- Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma (2022) (5)
- The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. (2014) (5)
- The role of cytoreductive nephrectomy for renal cell carcinoma in the era of targeted therapy (2008) (5)
- SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC). (2020) (5)
- National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. (2017) (5)
- Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: A systematic review and meta-analysis. (2013) (5)
- Impact of angiotensin system inhibitors (ASI) on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. (2014) (5)
- Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC). (2006) (5)
- Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. (2013) (5)
- Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium (2023) (5)
- Prognostic Significance of Increases in Hemoglobin in Renal Cell Carcinoma Patients During Treatment With VEGF‐directed Therapy (2017) (5)
- Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). (2020) (5)
- Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database (2018) (5)
- 2905 Genomic characterization of brain metastases and paired primary tumors reveals branched evolution and potential therapeutic targets (2015) (5)
- Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry (2020) (5)
- A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma. (2015) (5)
- New therapies for castrate-resistant prostate cancer (2011) (5)
- Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study. (2017) (5)
- Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design. (2015) (5)
- Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (4)
- First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2016) (4)
- Targeted therapies: Sunitinib in RCC—expanded access equals expanded benefit? (2009) (4)
- Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign (2019) (4)
- Recent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007 (2008) (4)
- Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. (2020) (4)
- Patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib in “real-world” clinical practice: Baseline characteristics and treatment efficacy (2008) (4)
- Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
- Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results from the International mRCC Database Consortium. (2013) (4)
- IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma (2022) (4)
- Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States (2022) (4)
- Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes. (2020) (4)
- Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study (2019) (4)
- The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage. (2022) (4)
- Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials (2021) (4)
- Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study (2022) (4)
- Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting. (2015) (4)
- The Effect of Weight Change During Treatment With Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma. (2019) (4)
- State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era. (2020) (4)
- Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. (2022) (4)
- Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC): An international mRCC database consortium (IMDC) analysis. (2020) (4)
- Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. (2021) (4)
- Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). (2019) (4)
- Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. (2013) (4)
- Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564 (2018) (4)
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) (2012) (4)
- Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. (2021) (4)
- Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors. (2021) (4)
- 851PDSubgroup analyses from KEYNOTE-045: Pembrolizumab (pembro) versus individual investigator’s choice of chemotherapy (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (uc) (2017) (4)
- THE 2017 AMERICAN JOINT COMMITTEE ON CANCER EIGHTH EDITION CANCER STAGING MANUAL: CHANGES IN STAGING GUIDELINES FOR CANCERS OF THE KIDNEY, RENAL PELVIS AND URETER, BLADDER, AND URETHRA: MP86‐17 (2017) (4)
- Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes (2020) (4)
- First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape (2022) (4)
- Quality of life (QoL) in the phase 3 METEOR trial of cabozantinib vs everolimus for advanced renal cell carcinoma (RCC) (2016) (4)
- Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma (2018) (4)
- Sunitinib in renal-cell carcinoma: expanded indications. (2009) (4)
- Risk of venous thromboembolism in cancer patients treated with cisplatin: A systematic review and meta-analysis. (2012) (4)
- RETRACTED: Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals (2019) (4)
- Incidence and risk of infections in renal cell cancer (RCC) and non-RCC patients treated with everolimus and temsirolimus: A meta-analysis of randomized control trials. (2013) (4)
- Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
- Renal-cell carcinoma in 2016: Advances in treatment — jostling for pole position (2017) (4)
- Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. (2017) (4)
- Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. (2022) (4)
- The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas. (2015) (4)
- Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
- Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER. (2022) (4)
- Overtreatment of low-risk prostate cancer in the United States: Incidence, cost, complications, and implications for the screening debate. (2013) (4)
- Comment on: Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma (2008) (4)
- Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. (2022) (4)
- Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts (2020) (4)
- FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma (2021) (4)
- Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma (2022) (4)
- IL 8 polymorphisms and overall survival in pazopanib-or sunitinib-treated patients with renal cell carcinoma (2017) (4)
- Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2017) (4)
- Data on Medicare eligibility and cancer screening utilization (2016) (4)
- CDKN2A alterations as markers of immune checkpoint blockade (ICB) resistance in urothelial carcinoma (UC). (2021) (4)
- Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC). (2013) (4)
- MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data. (2020) (4)
- Depth of response (DepOR) analysis and correlation with clinical outcomes from JAVELIN Renal 101. (2020) (4)
- Clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) and mammalian target of rapamycin inhibitors (mTORI) after immuno-oncology (IO) checkpoint inhibitors. (2018) (4)
- Impact of FGFR2/3 activating genomic alterations on response to enfortumab vedotin in metastatic urothelial carcinoma (mUC). (2021) (4)
- Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer. (2015) (4)
- Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (2011) (3)
- Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. (2009) (3)
- 656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC) (2021) (3)
- Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC). (2017) (3)
- Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma. (2015) (3)
- Correlation between findings from comprehensive genomic profiling and targeted therapy response in metastatic renal cell carcinoma. (2016) (3)
- Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. (2022) (3)
- Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma (2020) (3)
- Aggressive Electrolytes Replacement in Multiple Myeloma (MM) Patients Receiving Arsenic Trioxide (ATO) Containing Regimens Alleviates the Need for Frequent Electrocardiogram (ECG) Monitoring. (2005) (3)
- Germline variants in urothelial carcinoma: Analysis of pathogenic and likely pathogenic variants in 645 subjects. (2019) (3)
- Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (2015) (3)
- A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC). (2021) (3)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (3)
- Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). (2021) (3)
- Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101. (2021) (3)
- Safety and efficacy of restarting immune checkpoint inhibitors (CPI) after immune-related adverse events (irAEs) in metastatic renal cell carcinoma (mRCC). (2019) (3)
- Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC). (2021) (3)
- Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: A genomically annotated tool to improve stratification of patients (pts) with advanced renal cell carcinoma (RCC). (2018) (3)
- Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2015) (3)
- Comprehensive genomic profiling of 443 cases of renal cell carcinoma to reveal frequent clinically relevant genomic alterations. (2015) (3)
- Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. (2015) (3)
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). (2022) (3)
- Neurotoxicities of Novel Non-Steroidal Anti-Androgens for Prostate Cancer: A Systematic Review and Meta-Analysis. (2021) (3)
- Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival. (2017) (3)
- Dissecting the immunogenomic biology of cancer for biomarker development (2020) (3)
- Second-line VEGF TKI after IO combination therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2020) (3)
- An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma (2022) (3)
- Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma (2021) (3)
- An exploratory study of radium-223 and vascular endothelial growth factor targeted therapy (VEGF TT) in patients (pts) with metastatic renal cell carcinoma (mRCC) and bone metastases (BM). (2017) (3)
- Bevacizumab (BEV) and the risk of arterial thromboembolic events (ATE) in patients with renal cell carcinoma and other cancers: A large comprehensive meta-analysis of more than 13,000 patients. (2010) (3)
- 491 TIME TRENDS IN THE UTILIZATION OF HIGHER-COST TREATMENTS FOR PROSTATE CANCER, 2002-2007 (2010) (3)
- Meta-analysis of disease free survival (DFS) as a surrogate for overall survival (OS) in localized renal cell carcinoma (RCC). (2017) (3)
- Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT). (2014) (3)
- Upper Tract Urothelial Carcinomas: Prognostic Factors and Outcomes in Patients With Non–Lymph Node Distant Metastasis (2017) (3)
- Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC). (2017) (3)
- Impact of statins on outcomes in patients (pts) with metastatic castration resistant prostate cancer (mCRPC): Post-hoc analysis of data from COU-AA-301 and COU-AA-302 trials. (2018) (3)
- Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. (2015) (3)
- Comprehensive genomic profiling (CGP) of advanced papillary renal cell carcinoma (PRCC) to reveal distinctions from TCGA dataset. (2017) (3)
- Safety and efficacy of immune checkpoint inhibitors (CPI) in metastatic renal cell cancer (RCC) and urothelial cancer (UC) patients (pts) with pre-existing autoimmune disorders (AD). (2019) (3)
- Pathogenicity of VHL variants in families with non-syndromic von Hippel-Lindau phenotypes: An integrated evaluation of germline and somatic genomic results. (2021) (3)
- Correlation of progression-free survival at 6 months (PFS6) with overall survival at 12 months (OS12) in an analysis of 10 trials of second-line therapy for advanced urothelial carcinoma (UC). (2012) (3)
- Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply. (2021) (3)
- Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). (2019) (3)
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. (2018) (3)
- Long-term response and time to response to pazopanib (PAZ) and sunitinib (SUN) in metastatic renal cell carcinoma (mRCC): COMPARZ subanalysis. (2017) (3)
- Results of the phase II TRAXAR study: A randomized phase II trial of axitinib and TRC105 (TRAX) versus axitinib (AX) alone in patients with advanced or metastatic renal cell carcinoma (mRCC) (2019) (3)
- OncoAlert Round Table Discussions: The Global COVID-19 Experience (2021) (3)
- Molecular characteristics of renal cell carcinoma (RCC) risk groups from JAVELIN Renal 101. (2020) (3)
- Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. (2023) (3)
- Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in advanced renal cell carcinoma (RCC) (2019) (3)
- Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. (2022) (3)
- Meta-analysis of the Impact of Androgen Deprivation Therapy on Cardiovascular Death in Patients with Prostate Cancer (2011) (3)
- Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. (2009) (3)
- Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease- (2013) (3)
- Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). (2021) (2)
- Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (2022) (2)
- Epigenomic charting and functional annotation of risk loci in renal cell carcinoma (2023) (2)
- Discontinuing VEGF-targeted therapy (VEGF-TT) for progression versus toxicity impacts outcomes of second-line therapies in metastatic renal cell carcinoma (mRCC). (2016) (2)
- A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk (2020) (2)
- 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564 (2021) (2)
- TRAXAR study: a randomized phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinoma (mRCC) (2016) (2)
- 417 Phase 3 study of pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib as first-line treatment for advanced renal cell carcinoma (2021) (2)
- JAVELIN: avelumab another spear to fight urothelial carcinoma. (2018) (2)
- Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (2011) (2)
- Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy (2008) (2)
- Breastfeeding and breast cancer risk by receptor status — a systematic review andmeta-analysis (2015) (2)
- Trends in neoadjuvant chemotherapy (NAC) use for muscle-invasive bladder cancer (MIBC): An updated report using the National Cancer Database (NCDB). (2016) (2)
- Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms. (2021) (2)
- Precision medicine approach in kidney cancer: A pan renal cell carcinoma (RCC) study across three cancer genome atlas (TCGA) datasets for clinically relevant target identification. (2015) (2)
- External Validation of the Association of Progression-Free Survival at 6 Months (PFS6) with Overall Survival at 12 Months (OS12) in Second-Line Therapy for Advanced Urothelial Carcinoma (UC) (2012) (2)
- The Metastatic Prostate Cancer project (MPCproject): Translational genomics through direct patient engagement. (2018) (2)
- Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. (2014) (2)
- Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2020) (2)
- A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer (2022) (2)
- Radiologic response (RR) by MRI in patients (pts) with muscle-invasive urothelial cancer (MIUC) undergoing neoadjuvant chemotherapy. (2013) (2)
- First-line therapy for metastatic renal cell carcinoma with pancreatic metastases: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2022) (2)
- Abstract A18: Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma (2017) (2)
- Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). (2013) (2)
- The use of prostate-specific antigen screening in purchased versus direct care settings: Data from the TRICARE military database (2017) (2)
- Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. (2022) (2)
- Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC) (2008) (2)
- Therapeutic radiation for breast cancer in BRCA mutation carriers and contralateral breast cancer (CBC) risk (2007) (2)
- The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. (2015) (2)
- Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma. (2020) (2)
- Adverse effects of ADT on cognitive function and dementia for men with prostate cancer: A meta-analysis and systematic review. (2017) (2)
- CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas. (2014) (2)
- First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An updated analysis from the International mRCC Database Consortium (IMDC). (2013) (2)
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. Reply. (2021) (2)
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy (2022) (2)
- Hematologic toxicities in renal cell carcinoma and other malignancies treated with bevacizumab: A meta-analysis of clinical trials. (2011) (2)
- 39 – Molecular Abnormalities in Kidney Cancer (2015) (2)
- Treatment Decisions for Patients with Cancer during the COVID-19 Pandemic. (2021) (2)
- Cell-free tumor DNA and TERT promoter mutations in bladder cancer. (2017) (2)
- Development and clinical validation of circulating tumor cell (CTC) biomarkers in clear cell renal cell carcinoma (ccRCC) for the OMNIVORE clinical trial. (2017) (2)
- PBRM1 loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinoma (2020) (2)
- Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival. (2016) (2)
- ABO blood group and risk of lethal prostate cancer. (2014) (2)
- ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203). (2018) (2)
- Abstract NG03: Genomic characterization of 101 brain metastases and paired primary tumors reveals patterns of clonal evolution and selection of driver mutations (2014) (2)
- Long-term survival results of a randomized phase III trial of vin fl unine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy † (2013) (2)
- Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. (2018) (2)
- Ultrasensitive detection of TCR hypervariable region in solid-tissue RNA-seq data (2016) (2)
- Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2018) (2)
- Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma (2018) (2)
- Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients. (2012) (2)
- Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals (2019) (2)
- Abstract 4541:METgene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor (2018) (2)
- Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study. (2020) (2)
- 854PDPazopanib (p) or sorafenib (s) + radium-223 (rad) in metastatic renal cell carcinoma (mrcc) with bone metastases (bm) (2017) (2)
- Pembrolizumab vs investigator-choice chemotherapy for previously treated advanced urothelial cancer: Phase 3 KEYNOTE-045 study (2017) (2)
- First-line (1L) immuno-oncology (IO) combination therapies in metastatic renal-cell carcinoma (mRCC): Results from the international mRCC database consortium (IMDC). (2019) (2)
- 717P Comparison of long-term survival and cost-effectiveness (CE) of first-line (1L) treatment options in advanced renal cell carcinoma (aRCC) with intermediate or poor (I/P) prognostic risk (2020) (2)
- Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). (2019) (2)
- Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. (2014) (2)
- A pooled analysis of the efficacy and safety of cabozantinib post immunotherapy in patients with advanced renal cell carcinoma. (2020) (2)
- Effectiveness of first-line immune checkpoint inhibitors (ICI) in advanced non-clear cell renal cell carcinoma (ccRCC). (2021) (2)
- Kidney Cancer, Version 3.2022 (2021) (2)
- PCN53 Grade 3/4 Adverse Event (AE) Costs of Nivolumab Plus Ipilimumab (N+I) Versus Nivolumab Plus Cabozantinib (N+C) and Pembrolizumab Plus Axitinib (P+A) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) (2021) (2)
- Characterization of Patients With Poor‐Risk Metastatic Renal‐Cell Carcinoma: Results From a Pooled Clinical Trials Database (2017) (2)
- The effect of abiraterone acetate treatment on CREB and the development of abiraterone acetate resistance in prostate cancer cells. (2020) (2)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression. (2017) (2)
- Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101. (2021) (2)
- 883PSynchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy (2017) (2)
- Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST. (2018) (2)
- FGFR3 protein expression and gene mutation in primary and metastatic urothelial carcinoma (UC) tumors. (2012) (2)
- Risk factors and a model to predict toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: Results from the International Metastatic RCC Database Consortium. (2015) (2)
- Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC): CheckMate 9ER updated results. (2022) (2)
- Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. (2018) (2)
- Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma (2022) (2)
- Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma. (2010) (2)
- Adjuvant Chemotherapy for Bladder Cancer: Using Population-Based Data to Fill a Void of Prospective Evidence. (2016) (2)
- Risk of congestive heart failure with VEGF-targeted therapy: A systematic review and meta-analysis of clinical trials. (2010) (2)
- Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. (2018) (2)
- Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy (2019) (1)
- Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC). (2017) (1)
- Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
- FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians. (2018) (1)
- Impact of neoadjuvant immune checkpoint inhibitor therapy on primary tumor size and complexity: Correlation with surgical quality and short term oncological outcomes. (2022) (1)
- 11C‐METHIONINE POSITRON‐EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET‐CT) IN EVALUATING METASTATIC TRANSITIONAL CELL CARCINOMA RESPONSE TO SUNITINIB THERAPY (2010) (1)
- Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy. (2018) (1)
- B2B: Kidney Cancer Summary (2021) (1)
- Clinical outcomes by nephrectomy status in METEOR, a randomized phase 3 trial of cabozantinib (cabo) vs everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC). (2017) (1)
- Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. (2020) (1)
- Metastatic renal cell carcinoma: A guide to therapy based on current evidence (2009) (1)
- Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC). (2018) (1)
- COMPARATIVE EFFECTIVENESS OF SELECTIVE ADJUVANT VERSUS SYSTEMATIC NEOADJUVANT CHEMOTHERAPY‐BASED STRATEGY FOR MUSCLE‐ INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER: PD62‐01 (2017) (1)
- Comparative effectiveness of radical cystectomy versus bladder-sparing treatment for muscle-invasive urothelial carcinoma: A population-based report. (2014) (1)
- Cell-free methylated DNA (cfMeDNA) immunoprecipitation and high throughput sequencing technology (cfMeDIP-seq) in patients with clear cell renal cell carcinoma (ccRCC). (2019) (1)
- Association of hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ with UGT1A1 polymorphisms. (2013) (1)
- Safety and efficacy of CDX-014, an antibody-drug conjugate against T Cell immunoglobulin mucin-1 (TIM-1), in advanced renal cell carcinoma (2019) (1)
- Meta-Analysis of Long-term Results of Randomized Trials of the Impact of Adjuvant Radiation on Overall, Metastasis-Free, and Biochemical Recurrence-Free Survival for pT3N0 or Margin-Positive Prostate Cancer (2013) (1)
- Safety and Efficacy of Stereotactic MRI-Guided Adaptive Radiation Therapy for Localized Kidney Cancer (2022) (1)
- Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis. (2017) (1)
- NCCN Kidney Cancer Clinical Practice Guidelines in Oncology (2011) (1)
- Risk of bleeding not increased by sorafenib or sunitinib – Authors' reply (2010) (1)
- Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC). (2022) (1)
- Prognostic significance of bone metastases (BM) and bisphosphonate (BIS) therapy in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs). (2013) (1)
- Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma (mRCC) treated with targeted therapy: Results from the International mRCC Database Consortium. (2012) (1)
- The very favorable metastatic renal cell carcinoma (mRCC) risk group: Data from the International Metastatic RCC Database Consortium (IMDC). (2021) (1)
- A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). (2012) (1)
- Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's) (2007) (1)
- Management of biochemical recurrence after localized treatment for prostate cancer (2012) (1)
- Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis. (2017) (1)
- Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma. (2022) (1)
- Abstract PS7-01: Characteristics and outcomes of SARS-CoV-2 infection in patients with invasive breast cancer (BC) from the COVID-19 and cancer consortium (CCC19) cohort study (2021) (1)
- P226 FRACTION-RCC: a randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology agents in patients with advanced RCC. (2017) (1)
- Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and 99mTc-MDP Bone Scan in a Prospective Clinical Trial (2019) (1)
- Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. (2023) (1)
- Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy. (2017) (1)
- Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). (2021) (1)
- Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC). (2019) (1)
- First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An analysis from the International mRCC Database Consortium. (2013) (1)
- Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy. (2018) (1)
- Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort. (2015) (1)
- Older Age and Increasing Gleason Score: Implications for Prostate Cancer Screening (2015) (1)
- 395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC) (2014) (1)
- Temporal changes in the screening, diagnosis and surgical treatment of genitourinary (GU) malignancies during the COVID-19 pandemic. (2022) (1)
- Clinical correlation of circulating tumor cell (CTC) PD-L1 and HLA I expression in metastatic renal cell carcinoma (mRCC) using exclusion-based sample preparation technology. (2020) (1)
- The effect of SETD2 mutation (mts) on histone 3 lysine 36 tri-methylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ. (2014) (1)
- PD04-05 TRENDS OF METASTASECTOMY FOR METASTATIC RENAL CELL CARCINOMA AND THEIR IMPACT ON OVERALL SURVIVAL (2016) (1)
- Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR) (2017) (1)
- Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC). (2022) (1)
- Analysis of overall survival (OS) based on tumor target lesion change in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). (2017) (1)
- Comprehensive kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC). (2014) (1)
- CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2022) (1)
- Assessment of metastasectomy complications in renal cell carcinoma. (2016) (1)
- Impact of statins and survival outcomes in patients with metastatic renal cell carcinoma. (2015) (1)
- A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. (2015) (1)
- Outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first-line Immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials. (2020) (1)
- MP13-13 PROPENSITY MATCHED COMPARISON OF MORBIDITY AND COSTS OF OPEN VS. MINIMALLY INVASIVE RADICAL NEPHROURETERECTOMY: A CONTEMPORARY POPULATION-BASED ANALYSIS IN THE UNITED STATES (2014) (1)
- Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
- 4LBA Cabozantinib versus everolimus in patients with advanced renal cell carcinoma: Results of the randomized phase 3 METEOR trial (2015) (1)
- Analgesic use and the risk of renal cell carcinoma (RCC): Results from a large up-to-date meta-analysis. (2012) (1)
- Unusual Cutaneous Malignancies (2006) (1)
- BRCA mutation status and risk of secondary malignancy following chemotherapy for breast cancer (2007) (1)
- Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564. (2018) (1)
- Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. (2019) (1)
- First-, second-, third-line therapy for metastatic renal cell carcinoma (mRCC): Benchmarks for trials design from the International mRCC Database Consortium (IMDC). (2013) (1)
- The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). (2016) (1)
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma. (2018) (1)
- T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade. (2016) (1)
- 1075TiPKEYNOTE-029: PHASE 1/2 STUDY OF MK-3475 IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2B (PEG-IFN) OR IPILIMUMAB (IPI) IN PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) OR RENAL CELL CARCINOMA (RCC). (2014) (1)
- Effect of baseline characteristics, including antihypertensive therapy, on survival and hypertension during treatment with vascular endothelial growth factor (VEGF) signaling pathway inhibitors (VSP-Is). (2014) (1)
- Understanding Hospital-Level Patterns of Nonoperative Management for Low-risk Thyroid and Kidney Cancer (2022) (1)
- Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. (2011) (1)
- Genomic alterations in upper tract urothelial carcinoma (UTUC) versus urothelial carcinoma of the bladder (UBC). (2016) (1)
- Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. (2018) (1)
- Analgesic use and the risk of renal cell carcinoma (RCC): Results from a large up-to-date meta-analysis. (2012) (1)
- A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma. (2023) (1)
- Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study. (2016) (1)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
- Hematology and Oncology (2014) (1)
- MP41-09 QUALITY OF CARE IN THE TREATMENT OF LOCALIZED INTERMEDIATE AND HIGH RISK PROSTATE CANCER AT MINORITY SERVING HOSPITALS (2019) (1)
- 717TiP Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC) (2021) (1)
- The adverse effects of androgen-deprivation therapy: Comparison between gonadotropin-releasing hormone agonists and orchiectomy in the SEER-Medicare population. (2016) (1)
- CD73 expression in primary and metastatic renal cell carcinoma (RCC). (2018) (1)
- Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. (2020) (1)
- VARIATION IN THE USE OF ACTIVE SURVEILLANCE FOR LOW‐RISK PROSTATE CANCER: PD28‐06 (2017) (1)
- The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy. (2016) (1)
- Cabozantinib (C) exposure-response (ER) modeling of safety endpoints in patients (pts) with renal cell carcinoma (RCC) in the phase III METEOR study. (2017) (1)
- Proteomic stratification of clear cell renal cell carcinoma utilizing The Cancer Genome Atlas (TCGA) with external validation. (2015) (1)
- Triethylene Glycol can be Pre-Deployed as a Safe Virus-Killing Indoor Air Treatment. (2022) (1)
- Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). (2021) (1)
- Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) (2016) (1)
- Reply to B. Rini et al and S. Buti et al. (2017) (1)
- Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). (2016) (1)
- Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium. (2016) (1)
- Corrigendum re "Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma" [Eur Urol 2017;72:747-54]. (2018) (1)
- Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications. (2016) (1)
- Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials. (2015) (1)
- Evaluation of cabozantinib (cabo) in combination with direct oral anticoagulants (DOAC) or low molecular weight heparin (LMWH) in renal cell carcinoma (RCC). (2021) (1)
- Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. (2023) (1)
- Abstract 3159: Identification of circulating tumor cells from renal cell carcinoma patients by a multi-parameter flow cytometry assay (2016) (1)
- Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival. (2016) (1)
- Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial. (2022) (1)
- Predicting outcome in metastatic urothelial cancer (UC) receiving docetaxel (DT): miRNA profiling in pre and post therapy. (2015) (1)
- Germline alterations in urothelial carcinoma (UC) patients with family history of UC. (2019) (1)
- Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration. (2020) (1)
- Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition. (2012) (1)
- Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma (2017) (1)
- The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM (2009) (1)
- Perioperative immunotherapy for renal cell carcinoma: looking beyond the data (2022) (1)
- Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. (2012) (1)
- Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC). (2018) (1)
- Ruffling the Immunotherapy Response Paradigm with a Novel Personalized Peptide Vaccine. (2016) (1)
- Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study (2017) (1)
- 233PPHASE 2 CLINICAL EVALUATION OF PRECLINICALLY DEFINED BIOMARKERS FOR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) TYROSINE KINASE INHIBITOR (TKI) TIVOZANIB IN RENAL CELL CARCINOMA (RCC). (2014) (1)
- Prognostic Stratification of Advanced Urothelial Carcinoma (UC) Receiving Second-Line Systemic Therapy Including Time from Prior Chemotherapy (TFPC) as a Prognostic Factor (2012) (1)
- Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC). (2021) (1)
- Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder (2017) (1)
- Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial (2016) (1)
- Paradoxical significance of endorectal MRI (erMRI) response to neoadjuvant chemotherapy in patients with high-risk localized prostate cancer (HRLPC). (2013) (1)
- Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial (2019) (1)
- 925TiPA phase 2 study of investigational TORC1/2 inhibitor TAK-228 and TAK-228 plus investigational PI3Kα-selective inhibitor TAK-117 vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma (ccRCC) that has progressed on VEGF-targeted therapy (2017) (1)
- 9p21 Loss Defines the Evolutionary Patterns of Aggressive Renal Cell Carcinomas (2020) (1)
- Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial (2017) (1)
- Incidence and risk of congestive heart failure risk in renal cell cancer (RCC) and non-RCC patients treated with sunitinib. (2011) (1)
- Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study. (2022) (1)
- Racial Disparities in the Management of African American Men With Intermediate- to High-Risk Prostate Cancer (2014) (1)
- miR125 and miR200a as potential circulating miRNA biomarkers in metastatic urothelial carcinoma patients treated with docetaxel. (2015) (1)
- Distinct MET alterations to induce a common phenotype and to define a MET-driven subset of papillary RCC: Results from the Cancer Genome Atlas (TCGA) Kidney Renal Papillary (KIRP) Working Group. (2015) (1)
- Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy (2022) (1)
- Abstract 2976: Comprehensive Pan-Genomic characterization of adrenocortical carcinoma (2015) (1)
- Abstract CT090: A phase 1b/2 study of ramucirumab in combination with emibetuzumab in patients with advanced solid tumors (2017) (1)
- PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target? (2012) (1)
- Differential Postprostatectomy Cancer-Specific Mortality of Occult T3 Versus Clinical T3 Prostate Cancer: Implications for Radiation Managed Patients Upstaged on Prostate MRI (2015) (1)
- Efficacy of local treatment in patients with prostate cancer with clinically pelvic lymph node-positive disease at initial diagnosis. (2017) (1)
- MK-6482, a hypoxia-inducible factor 2α inhibitor (HIF-2α), versus everolimus in heavily pretreated, immune checkpoint–inhibitor-resistant, advanced clear cell renal cell carcinoma (ccRCC): Phase III study. (2021) (1)
- CLINICAL FEATURES AND OUTCOMES OF CARDIAC INVOLVEMENT IN PATIENTS WITH CANCER TREATED WITH IMMUNE CHECKPOINT INHIBITORS (2023) (0)
- Characteristics of metastatic renal cell carcinoma (mRCC) patients treated with delayed targeted therapy: Results from the International mRCC Consortium (IMDC). (2015) (0)
- ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinium-based chemotherapy: A systematic review and meta-analysis. (2015) (0)
- Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies (2022) (0)
- Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. (2012) (0)
- A video-based, personalized web page (VBPWP) as a complement to clinical trial (CT) patient management. (2017) (0)
- Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. (2010) (0)
- Variation in positive surgical margin status following radical prostatectomy for pT2 prostate cancer (2019) (0)
- Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (2022) (0)
- Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy. (2013) (0)
- Assessment of the Ecological Association between Tobacco Smoking Exposure and Bladder Cancer Incidence over the Past Half-Century in the United States (2017) (0)
- 665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101 (2021) (0)
- 1107 Outcomes of patients with non clear cell renal cell carcinoma treated with targeted therapy and prognostication using the International mRCC Database Consortium Criteria (2013) (0)
- Abstract 3866: Targeting AXL can effectively inhibit c-Met-induced therapeutic resistance in renal cancer (2023) (0)
- Patient outcomes based on prognostic risk groups in METEOR, a randomized phase 3 study of cabozantinib (cabo) versus everolimus (eve) in patients (pts) with advanced renal cell carcinoma (RCC) (2016) (0)
- Contemporary national trends in prostate cancer risk profile at diagnosis (2019) (0)
- 865PTHE SIGNIFICANCE OF COMPLETE RESPONSE (CR) IN PATIENTS RECEIVING SALVAGE THERAPY FOR ADVANCED UROTHELIAL CARCINOMA (UC). (2014) (0)
- Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC). (2011) (0)
- Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). (2021) (0)
- 755 Trends of metastasectomy for metastatic renal cell carcinoma and their impact on overall survival (2016) (0)
- Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. (2022) (0)
- Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) (2016) (0)
- ADJUVANT CHEMOTHERAPY VS. OBSERVATION FOLLOWING RADICAL CYSTECTOMY FOR PT3‐4 AND/OR PN+ UROTHELIAL CARCINOMA OF THE BLADDER PREVIOUSLY TREATED WITH NEOADJUVANT CHEMOTHERAPY: PD62‐02 (2017) (0)
- Phase 3 LITESPARK-022: Pembrolizumab (pembro) plus hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan as adjuvant treatment for clear cell renal cell carcinoma (ccRCC). (2023) (0)
- COVID-19 in cancer patients: Update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases (2023) (0)
- Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. (2012) (0)
- Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (2015) (0)
- MP73-11 ANDROGEN DEPRIVATION THERAPY AND INCREASED NON-CANCER MORTALITY IN PROSTATE CANCER PATIENTS: ANALYSIS OF THE NUMBER NEEDED TO TREAT (2015) (0)
- Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States. (2015) (0)
- Aurora kinase-mTOR signaling in sarcomatoid mRCC 1 RNA-seq Reveals Aurora Kinase Driven-mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2014) (0)
- Abstract S06-02: Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study (2021) (0)
- COMPARATIVE EFFECTIVENESS OF TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY FOR LOCALIZED MUSCLE‐INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER: PD62‐12 (2017) (0)
- Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2017) (0)
- Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study (2021) (0)
- MP72-19 DECREASED UTILIZATION OF LOW-VALUE HEALTH CARE SERVICES DURING THE COVID-19 PANDEMIC (2023) (0)
- Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (0)
- MP60-01 PREVALENCE OF NON-RECOMMENDED SCREENING FOR PROSTATE CANCER AND BREAST CANCER IN THE UNITED STATES (2015) (0)
- C-reactive protein (CRP) as a predictive marker for outcomes with avelumab + axitinib (A + Ax) in patients with poor-risk advanced renal cell carcinoma (aRCC): Exploratory analysis from JAVELIN Renal 101. (2023) (0)
- IL-8 and cancer prognosis on immunotherapy (2020) (0)
- Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study. (2021) (0)
- Characterization of clinical outcomes among patients with advanced chromophobe renal cell carcinoma (ChRCC) treated with first-line immunotherapy (IO)-based regimens. (2023) (0)
- Title: Sex Specific Associations in Genome Wide Association Analysis of Renal Cell Carcinoma (2019) (0)
- Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma (2020) (0)
- PD15-12 HEALTH CARE SPENDING IN HIGH RESOURCE PROSTATE CANCER PATIENTS: WHAT CONTRIBUTES MOST TO HIGH PROSTATE CANCER HEALTH CARE COSTS? (2019) (0)
- The impact of treatment at minority-serving hospitals on outcomes for bladder cancer. (2018) (0)
- Related articles (2013) (0)
- Adjuvant chemotherapy for upper-tract urothelial carcinoma: A systematic review and meta-analysis of available studies. (2014) (0)
- Patient-reported outcomes: what really matters to patients? - Authors' reply. (2022) (0)
- Towards a Better Understanding of Antibody-Drug Conjugates in Urothelial Carcinoma. (2022) (0)
- Biomarker-based phase II study of sapanisertib (TAK-228), an mTORC1/2 inhibitor in patients with refractory metastatic renal cell carcinoma (mRCC). (2021) (0)
- Re : The Relationship between the Extent of Extraprostatic Extension and Survival following Radical Prostatectomy (2015) (0)
- Abstract B87: Analgesics use increase the risk of renal cell carcinoma (RCC): Results from a large up-to-date meta-analysis (2011) (0)
- Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma (2019) (0)
- MP25-08 DETERMINANTS OF PROSTATE CANCER SCREENING IN ASIAN AMERICANS (2016) (0)
- Germline variants across self-reported racial populations with urothelial carcinoma (UC). (2022) (0)
- Abstract 886: Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects (2023) (0)
- Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets. (2014) (0)
- 872POutcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) (2017) (0)
- Virtual consults: A paradigm shift for second opinions in oncology care. (2016) (0)
- Fixed tissue ChIP-seq (FiT-Seq) of archived FFPE clinical bladder cancer (BC) samples to reveal tumor-specific enhancer and super-enhancer profiles. (2016) (0)
- Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial. (2022) (0)
- Characterization of FOLH1 expression in renal cell carcinoma (RCC). (2023) (0)
- Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’ (2021) (0)
- Institutional retrospective review of presurgical cisplatin-based chemotherapy (chemo) in patients with urothelial carcinoma (UC): Gemcitabine+cisplatin (GC) versus dose-dense methotrexate, vinblastine, doxorubicin, cisplatin (ddMVAC). (2015) (0)
- Evaluation of the novel “trial within a trial” design of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC) (2016) (0)
- Abstract 4727: Genomic characterization of brain metastases reveals divergent evolution and metastasis specific mutations (2015) (0)
- Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
- CLINICAL OUTCOMES AND TOXICITY PROFILE OF PATIENTS WITH PRIMARY CARDIAC TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS (2023) (0)
- Genetic polymorphisms’ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents. (2012) (0)
- RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. (2021) (0)
- Fatigue with vascular endothelial growth factor receptor tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors in patients with malignancies: A meta-analysis of randomized clinical trials. (2015) (0)
- Cancer Proceedings from the SIU B2B Uro-Oncology: GU Cancers Triad Virtual Meeting (2021) (0)
- Gleason 5 + 3=8 Prostate Cancer: Much More like Gleason 9? (2015) (0)
- 8 – Cancer of the Genitourinary Tract (2010) (0)
- Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. (2012) (0)
- MP63-17 TRENDS OF ACUTE KIDNEY INJURY AFTER RADICAL OR PARTIAL NEPHRECTOMY FOR RENAL CELL CARCINOMA (2015) (0)
- Androgen Deprivation Therapy for Prostate Cancer and Cardiovascular Death—Reply (2012) (0)
- External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC). (2012) (0)
- Impact of first-line platinum therapy on survival in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium (TCCU) treated with vinflunine. (2012) (0)
- Abstract 5122: Identification of PD-L1 expression on circulating tumor cells as a prognostic indicator in prospective clinical trial, OMNIVORE (2022) (0)
- The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts. (2015) (0)
- Integrated Clinico-Genomic Analysis of Genetic Ancestry in 1,614 Patients With Cancer Treated With Immune Checkpoint Inhibitors (2022) (0)
- FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials. (2020) (0)
- Genomic profiling of variant urinary tract tumor histologies. (2019) (0)
- Risk of secondary urinary bladder cancer (UBC) in patients receiving radiotherapy for rectal cancer, prostate cancer, and gynecologic malignancies. (2016) (0)
- Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation (2016) (0)
- Efficacy of Grignard Pure to Inactivate Airborne Phage MS2, a Common SARS-CoV-2 Surrogate (2023) (0)
- Assessing the Contemporary Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Another Step in the Right Direction. (2016) (0)
- Prevalence of pathogenic germline risk variants (PVs) in 1,829 renal cell carcinoma (RCC) patients (pts). (2020) (0)
- EFFICACY OF LOCAL TREATMENT IN PROSTATE CANCER PATIENTS WITH CLINICALLY PELVIC LYMPH NODE‐POSITIVE DISEASE AT INITIAL DIAGNOSIS: MP53‐18 (2017) (0)
- Impact of geographic region on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. (2017) (0)
- Comprehensive functional kinase profiling to classify clear cell (cc)-renal cell carcinoma (RCC). (2014) (0)
- PUK1 INCIDENCE AND COST OF ADVERSE EVENTS (AES) IN PATIENTS WITH RENAL CELL CARCINOMA (RCC) TREATED WITH ANGIOGENESIS INHIBITORS (AIS) (2010) (0)
- Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium. (2012) (0)
- Multidisciplinary team referral at diagnosis for patients with non-metastatic renal cell carcinoma. (2022) (0)
- Abstract SY25-02: Widespread germline-somatic regulatory differences in renal cell carcinoma prioritize risk mechanisms (2019) (0)
- Abstract 2351: AXL and c-MET cross-talk in the regulation of PD-L1 expression on renal cancer cells (2019) (0)
- Computed Tomography Texture Analysis for Predicting Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors (2022) (0)
- The list of novel agents for advanced renal cell carcinoma expands yet again (2010) (0)
- EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON‐METASTATIC MUSCLE‐INVASIVE URINARY BLADDER CANCER: MP34‐19 (2017) (0)
- In Reply (2017) (0)
- Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. (2014) (0)
- Detection of urothelial carcinoma using plasma cell-free methylated DNA. (2020) (0)
- Impact of #ASCO Twitter impressions on the oncology community. (2021) (0)
- Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies. (2016) (0)
- Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial (2022) (0)
- Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database. (2015) (0)
- Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. (2012) (0)
- 295 Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects (2022) (0)
- PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY (2010) (0)
- The efficiency of Grignard Pure™ to inactivate airborne SARS-CoV-2 surrogate (2022) (0)
- Renal cell cancer (2011) (0)
- Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. (2022) (0)
- Genomic landscape of high-grade T1 micropapillary bladder tumors. (2015) (0)
- MP45-11 WHICH CLINICAL CHARACTERISTICS SHOULD PROMPT MULTIDISCIPLINARY TEAM EVALUATION AFTER DIAGNOSING NON-METASTATIC RENAL CELL CARCINOMA: IMPLICATIONS FOR PATIENT REFERRAL, PRE-SURGICAL TRIALS AND HEALTH CARE POLICIES (2021) (0)
- Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes. (2013) (0)
- MP71-03 VARIATION IN UNPLANNED THIRTY-DAY READMISSIONS ACROSS UNITED STATES COC-ACCREDITED FACILITIES AFTER RADICAL CYSTECTOMY FOR CARCINOMA OF THE BLADDER (2018) (0)
- PD37-01 CONTEMPORARY TRENDS IN TREATMENT PATTERNS FOR MEN DIAGNOSED WITH CLINICALLY LOCALIZED PROSTATE CANCER (2016) (0)
- Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC). (2019) (0)
- Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states (2023) (0)
- Patients' Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19. (2023) (0)
- Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial (2020) (0)
- Prostate cancer in the medicare shared savings program: are Accountable Care Organizations associated with reduced expenditures for men with prostate cancer? (2019) (0)
- Determinants of cancer screening in Asian-Americans (2016) (0)
- ABO blood group and risk of renal cell cancer. (2012) (0)
- Abstract A94: ABO blood group and risk of renal cell cancer (2011) (0)
- Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma (2022) (0)
- MP66-05 VARIATION IN POSITIVE SURGICAL MARGIN STATUS FOLLOWING RADICAL PROSTATECTOMY FOR PT2 PROSTATE CANCER (2019) (0)
- 726 Temporal trends in prostate cancer (PCa) risk group stratification following the 2008 United States preventive services task force recommendations (2016) (0)
- Abstract 17397: Cardiac Dysfunction Resulting From Therapeutic Inhibition of the Vascular Endothelial Growth Factor Signaling Pathway in Cancer Patients (2013) (0)
- Predictors of objective response to first-line immuno-oncology combination therapies in metastatic renal cell carcinoma: Results from the international metastatic renal cell database consortium (IMDC). (2022) (0)
- Does CARMENA mark the end of cytoreductive nephrectomy for metastatic renal cell carcinoma? (2019) (0)
- 638 Androgen deprivation therapy and increased non-cancer mortality in prostate cancer patients: Analysis of the number needed to harm (2015) (0)
- 437 Safety and efficacy of immune checkpoint inhibitors (ICI) in patients living with HIV (PLWH) and metastatic non-small cell lung cancer (NSCLC): a matched cohort study from the international CATCH-IT consortium (2022) (0)
- The Impact of Race on Prostate-Cancer Specific Mortality Among Men With Low-Risk Disease: Potential Implications for Active Surveillance (2014) (0)
- Acknowledgement to the Reviewers (2010) (0)
- RACIAL DISPARITIES IN DELIVERING DEFINITIVE THERAPY FOR INTERMEDIATE‐HIGH RISK LOCALIZED PROSTATE CANCER: THE IMPACT OF FACILITY FEATURES AND SOCIOECONOMIC CHARACTERISTICS: PD10‐10 (2017) (0)
- Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). (2017) (0)
- Efficacy of cabozantinib vs everolimus in advanced renal cell carcinoma with bone metastases: results from the phase 3 METEOR study (2017) (0)
- Phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced clear cell renal cell carcinoma (ccRCC). (2022) (0)
- A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801). (2021) (0)
- Abstract LB-279: Nonsteroidal anti-inflammatory drug (NSAID) use and risk of lethal renal cell carcinoma (2014) (0)
- Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. (2022) (0)
- Reply to C. Buttigliero et al and B. Biswas et al. (2017) (0)
- Urological Survey Urological Oncology : Adrenal , Renal , Ureteral and Retroperitoneal Tumors Re : ClearCode 34 : A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma (2014) (0)
- PD30-12 RISK OF DEMENTIA FOLLOWING ANDROGEN DEPRIVATION THERAPY FOR TREATMENT OF PROSTATE CANCER (2019) (0)
- Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC). (2016) (0)
- 1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials (2020) (0)
- 922TiPKEYNOTE-564: Phase 3 trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC) (2017) (0)
- Comparison VEGF-pathway elements and EMT markers in patients with sarcomatoid metastatic renal cell carcinoma and risk-matched controls. (2014) (0)
- Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication (2004) (0)
- Urachal versus nonurachal adenocarcinomas of the bladder: A population-based report. (2016) (0)
- CONTEMPORARY INCIDENCE AND EPIDEMIOLOGIC TRENDS OF BRAIN METASTASES AT RENAL CELL CARCINOMA DIAGNOSIS: MP22‐18 (2017) (0)
- Genomics RNA-seq Reveals Aurora Kinase – Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2015) (0)
- Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. (2020) (0)
- Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI). (2022) (0)
- Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data. (2021) (0)
- Incidence of reduced penis size among men with recurrent prostate cancer previously treated with surgery, radiation plus androgen deprivation, or radiation alone. (2012) (0)
- Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC). (2021) (0)
- Emerging and Novel Therapeutic Targets in Renal Cancer (2011) (0)
- Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). (2023) (0)
- Conditional immune adverse event rate in urothelial and renal cell carcinoma patients treated with immune checkpoint inhibitors. (2020) (0)
- Automated identification of immune related adverse events in oncology patients using machine learning. (2021) (0)
- Prognostic factors in patients treated with VEGF-targeted therapies. (2010) (0)
- Change in International mRCC Database Consortium (IMDC) prognostic category and implications for efficacy of second-line targeted therapy. (2016) (0)
- Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. (2023) (0)
- A phase II biomarker trial of everolimus in patients with advanced renal cell carcinoma (08-313). (2014) (0)
- 683P Impact of renin-angiotensin system inhibitors (RASi) on outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) (2021) (0)
- 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk (2020) (0)
- Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. (2023) (0)
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2020) (0)
- Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). (2019) (0)
- 742 A multicohort phase 1b study (STELLAR-002) of XL092 in combination with immunotherapy in patients with advanced solid tumors (2022) (0)
- Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. (2015) (0)
- Corrigendum to "Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma" [Eur Urol 2023]. (2023) (0)
- Using novel protein antibodies on tissue microarrays (TMAs) for breast cancer prognostication. (2004) (0)
- Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients. (2012) (0)
- Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma (2018) (0)
- Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC). (2019) (0)
- FOXP3+ T-cell infiltration is associated with improved outcomes in metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICI). (2022) (0)
- Sequential Response to FGFR3 Inhibition With Subsequent Exceptional Response to Atezolizumab in a Patient With FGFR3-TACC3 Fusion-Positive Metastatic Urothelial Carcinoma. (2018) (0)
- Reply to impact of postoperative prostate‐specific antigen disease recurrence and the use of salvage therapy on the risk of death (2011) (0)
- 7 Characterizing the impact of lymph node metastases on survival outcome of metastatic renal cell carcinoma patients treated with targeted therapies (2015) (0)
- Health-related quality of life (HRQoL) in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: Five-year follow-up results. (2022) (0)
- Facility Level Variation in Rates of Definitive Therapy for Low Risk Prostate Cancer in Men with Limited Life Expectancy: An Opportunity for Value Based Care Redesign. (2018) (0)
- 2651 Comprehensive genomic profiling (CGP) identifies unique and abundant clinically relevant genomic alterations in rare histologies of renal cell carcinoma (2015) (0)
- PD24-01 DOES TUMOR SIZE AT THE TIME OF CYTOREDUCTIVE NEPHRECTOMY INFLUENCE SURVIVAL? (2018) (0)
- Adjuvant pembrolizumab (pembro) for renal cell carcinoma (RCC) across UCLA Integrated Staging System (UISS) risk groups and disease stage: Subgroup analyses from the KEYNOTE-564 study. (2023) (0)
- Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. (2020) (0)
- Proton pump inhibitors (PPIs) and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). (2017) (0)
- 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC) (2020) (0)
- The Evolv ing Landscape of Metastat ic Renal Cel l Carc inoma (2012) (0)
- Comorbidity, Body Mass Index, and Age and the Risk of Non-prostate Cancer-specific Mortality following a Postradiation PSA Recurrence (2009) (0)
- Retrospective analysis of risk factors for fatigue in clinical trial patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (0)
- Abstract 2814: Anti-CAIX Immune Restoring (IR) CAR-T cells display superior antitumor activity and reverse immunosuppressive TME in a humanized ccRCC orthotopic mouse model (2022) (0)
- Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. (2012) (0)
- Reply to D.R. Minor (2010) (0)
- Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC. (2018) (0)
- Issue information (2013) (0)
- Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. (2023) (0)
- Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium. (2012) (0)
- Sex specific associations in genome wide association analysis of renal cell carcinoma (2019) (0)
- PCN127 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB COMPARED WITH CURRENTLY AVAILABLE FIRST-LINE TREATMENTS IN PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC RENAL CELL CARCINOMA IN THE UNITED STATES (2019) (0)
- Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). (2019) (0)
- Impact of SLCO1B3 single nucleotide polymorphisms (SNPs) on outcomes in patients with castration resistant prostate cancer (CRPC) treated with docetaxel. (2018) (0)
- Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials. (2017) (0)
- PROSTATE-SPECIFIC ANTIGEN RECURRENCE AFTER RADICAL PROSTATECTOMY AND THE RISK OF DEATH (2009) (0)
- Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) (2021) (0)
- Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC). (2016) (0)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (0)
- A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC). (2014) (0)
- Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy (2021) (0)
- COMPARATIVE EFFECTIVNESS OF ROBOT‐ASSISTED VS. OPEN RADICAL CYSTECTOMY: PD67‐09 (2017) (0)
- MP36-02 VALIDATION AND GENOMIC INTERROGATION OF THE MET VARIANT RS11762213 AS A PREDICTOR OF ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA (2014) (0)
- Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk. (2023) (0)
- A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (0)
- Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis. (2017) (0)
- Cell-free DNA analysis in renal cell carcinoma: Comparison with tumor sequencing and correlation with response to therapy. (2019) (0)
- Identification of ALK gene alterations in urothelial carcinoma (UC). (2011) (0)
- Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial (Preprint) (2018) (0)
- Abstract CT243: A phase 1b/2 umbrella study of investigational immune and targeted combination therapies for patients with advanced renal cell carcinoma (RCC) who progressed on PD-1/L1 and VEGF inhibitors (2021) (0)
- The Natural History of Renal-Cell Carcinoma with Sarcomatoid Differentiation, a Stage-by-Stage Analysis. (2022) (0)
- CLOVIZ: CLINICAL OUTCOMES VISUALIZATION OF IMDC CRITERIA IN METASTATIC RENAL CELL CARCINOMA FOR PATIENT‐CENTERED DECISION MAKING: PD06‐01 (2017) (0)
- Retraction: Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals (2020) (0)
- Comprehensive genomic profiling of 443 patients with advanced renal cell carcinoma (RCC) to reveal clinically relevant genomic alterations and to aid in classification of rare subtypes. (2015) (0)
- Cancer Therapy : Clinical Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma (2015) (0)
- Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC). (2015) (0)
- Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma (2022) (0)
- CLOVIZ: Clinical outcomes visualization of IMDC criteria in metastatic renal cell carcinoma for patient-centered decision making. (2017) (0)
- Characterization of mutational load in patients with advanced urothelial cancer. (2016) (0)
- 756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies (2016) (0)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (0)
- A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis (2019) (0)
- MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS (2014) (0)
- Nivolumab plus cabozantinib vs sunitinib for first-line treatment of advanced renal cell carcinoma (aRCC): 3-year follow-up from the phase 3 CheckMate 9ER trial. (2023) (0)
- An exploratory study to investigate the immunomodulatory activity of BMS-936558 in patients with metastatic clear-cell renal cell carcinoma. (2012) (0)
- Pembrolizumab in patients with Bacillus Calmette Guérin (BCG)-unresponsive, high-risk non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 study (2016) (0)
- Characterization of patients (pts) with poor risk metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. (2017) (0)
- Impact of metformin on outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC): Results from a pooled clinical trials database. (2016) (0)
- Predictive and pharmacodynamic biomarkers of kinase inhibitors in renal cell carcinoma circulating tumor cells using the versa platform. (2014) (0)
- CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS: MP88‐14 (2018) (0)
- Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. (2021) (0)
- MP47-18 SUSTAINABLE MULTIDISCIPLINARY TEAM REFERRAL FOR NON-METASTATIC RENAL CELL CARCINOMA: A SURVIVAL-BASED RECOMMENDATION (2022) (0)
- thanks to referees 2014 (2014) (0)
- Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design. (2013) (0)
- Patient risk factors and pegfilgrastim use in cabazitaxel-treated prostate cancer pateints in an academic setting. (2014) (0)
- 817PPROGNOSTIC IMPACT OF CHANGE IN NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IN RESPONSE TO TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (0)
- Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma (2023) (0)
- Comprehensive analysis of five key immune related adverse events (irAE) from immune checkpoint blockers (ICB) CTLA-4 and PD-1 inhibitors in cancer patients. (2016) (0)
- MP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA (2017) (0)
- Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (0)
- Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
- MP03-15 TRENDS IN TREATMENT STRATEGIES FOR METASTATIC RENAL CELL CARCINOMA (2016) (0)
- 1389 COMPARATIVE EFFECTIVENESS AND COSTS OF ROBOTIC-ASSISTED LAPAROSCOPIC VERSUS OPEN RADICAL CYSTECTOMY (2012) (0)
- PD04-06 CYTOREDUCTIVE NEPHRECTOMY IN THE TARGETED THERAPY ERA: AN ANALYSIS OF THE NATIONAL CANCER DATA BASE (2016) (0)
- Delayed PSA responses in metastatic castration resistant prostate cancer (mCRPC) patients (pts) treated with sipuleucel-T. (2018) (0)
- Deferred cytoreductive nephrectomy among patients with newly diagnosed metastatic renal cell carcinoma treated initially with sunitinib. (2019) (0)
- Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial. (2017) (0)
- Comprehensive genomic characterization of urothelial carcinomas. (2018) (0)
- Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. (2014) (0)
- MP50-07 THE ASSOCIATION BETWEEN OBESITY AND INCIDENCE OF TOTAL AND FATAL RENAL CELL CARCINOMA IN TWO PROSPECTIVE COHORTS (2015) (0)
- Statin use and risk of renal cell carcinoma in three prospective cohort studies. (2018) (0)
- PCN92 Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib (N+C) Versus Sunitinib (S) for Previously Untreated Advanced Renal Cell Carcinoma (aRCC) (2021) (0)
- Abstract 4585: Development of multi-marker capture and analysis of circulating tumor cells in renal cell carcinoma (2018) (0)
- Access to definitive treatment and survival for intermediate-risk and high-risk prostate cancer at hospital systems serving health disparity populations. (2022) (0)
- Pathologic outcomes at cytoreductive nephrectomy (CN) following immunotherapy (IO) for patients with advanced renal cell carcinoma (RCC). (2022) (0)
- Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma (2018) (0)
- 888PChange in neutrophil-to-lymphocyte ratio (NLR) in response to immunotherapy for metastatic renal cell carcinoma (mRCC) (2017) (0)
- Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. (2021) (0)
- Pan-urologic cancer genomic subtypes that transcend tissue of origin (2017) (0)
- Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers. (2016) (0)
- 239 Efficacy and toxicity of single agent immune checkpoint inhibitors among adults with cancer aged ≥80 years: a multicenter international cohort study (2021) (0)
- Association of gene expression with outcomes with everolimus as post-VEGF inhibitor therapy for renal cell carcinoma (RCC). (2018) (0)
- Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC). (2013) (0)
- Contemporary incidence and epidemiologic trends of brain metastases at renal cell carcinoma diagnosis (2017) (0)
- Clarification needed for pembrolizumab as adjuvant therapy in clear cell renal cell carcinoma - Authors' reply. (2023) (0)
- Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma. (2022) (0)
- Impact of concurrent ACE inhibitors and ARBs on outcomes with immune-checkpoint inhibitors (ICIs) for patients (pts) with metastatic renal cell carcinoma (mRCC). (2021) (0)
- EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA: MP71‐09 (2017) (0)
- Renal cell carcinoma (RCC) primary tumor shrinkage on vascular endothelial growth factor (VEGF)-targeted therapy (TT): A pooled analysis. (2018) (0)
- The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). (2021) (0)
- Bladder Cancer: Upper Tract Transitional Cell Carcinoma IMP71-09 EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA (2017) (0)
- Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (0)
- 1165PImmune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas (2017) (0)
- Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers. (2021) (0)
- 556 Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): analysis from CheckMate 214 (2022) (0)
- Safety and efficacy of retreatment with immune checkpoint inhibitors (ICIs) in patients with metastatic RCC (mRCC) who have previously received an ICI. (2020) (0)
- MP73-20 ANALGESIC USE AND RISK OF RENAL CELL CANCER: RESULTS FROM TWO PROSPECTIVE COHORT STUDIES (2016) (0)
- OP-JNCI200067 1..10 (2020) (0)
- Integrative Analysis of Germline Rare Variants in Clear and Non-Clear Cell Renal Cell Carcinoma (2023) (0)
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma (2023) (0)
- Improving tumor mutational burden calibration in non-European patients. (2021) (0)
- Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma (2015) (0)
- Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). (2012) (0)
- 701O Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing (2020) (0)
- Outcomes of patients with brain metastases from renal cell carcinoma treated with first-line therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). (2023) (0)
- Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC). (2021) (0)
- The Prostate Cancer Project (PC Project): Translational genomics through direct patient engagement. (2017) (0)
- Impact of lymph node mets in mRCC. Eur Urol 2015 (2015) (0)
- HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer (2021) (0)
- The impact of weight change during treatment with targeted therapy in patients with metastatic renal cell carcinoma (mRCC). (2016) (0)
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma (2018) (0)
- MP13-14 THE IMPACT OF SURGEON VOLUME ON THE MORBIDITY AND COSTS OF NEPHROURETERECTOMY IN THE UNITED STATES: A CONTEMPORARY POPULATION-BASED ANALYSIS (2014) (0)
- Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC). (2020) (0)
- National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer. (2017) (0)
- In Reply (2012) (0)
- Hypertension in patients treated with VEGF TKIs: A comprehensive, up-to-date systematic review and meta-analysis of randomized trials. (2014) (0)
- Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder (2017) (0)
- MP35-01 PROTEOMIC STRATIFICATION OF CLEAR CELL RENAL CELL CARCINOMA UTILIZING THE CANCER GENOME ATLAS (TCGA) WITH EXTERNAL VALIDATION (2015) (0)
- Hyperprogressive disease on immune checkpoint therapy in advanced solid malignancies: A systematic review. (2019) (0)
- Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. (2014) (0)
- PHASE 1 TRIALS OF ANTI-ENPP3 ANTIBODY DRUG CONJUGATES IN ADVANCED REFRACTORY RENAL CELL CARCINOMAS (2018) (0)
- RCC New drugs—where do they fit? What does the future hold? (2017) (0)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (0)
- Cabozantinib in combination with atezolizumab in non-clear cell renal cell carcinoma: Extended follow-up results of cohort 10 of the COSMIC-021 study. (2023) (0)
- Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) (2018) (0)
- MP77-12 CONTEMPORARY PATTERNS OF SELF-REPORTED PSA SCREENING IN U.S. VETERANS (2015) (0)
- MP79-10 PHARMACOVIGILANCE ANALYSIS OF MELANOMA ADVERSE EVENTS IN MEN TREATED WITH SILDENAFIL FOR ERECTILE DYSFUNCTION (2023) (0)
- 132 COST-EFFECTIVENESS ANALYSIS OF PERCUTANEOUS RENAL MASS BIOPSY TO GUIDE THE SURGICAL MANAGEMENT OF SMALL RENAL MASSES (2012) (0)
- Ethnicity-Specific Variation in the Germline Landscape of Renal Cell Carcinoma (2020) (0)
- 425P The impact of obesity on treatment outcomes in patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents (2020) (0)
- Prostate Cancer: Detection & Screening IIIMP21-05 TEMPORAL TRENDS IN PROSTATE CANCER RISK GROUP STRATIFICATION FOLLOWING THE 2008 UNITED STATES PREVENTIVE SERVICES TASK FORCE RECOMMENDATIONS (2016) (0)
- PLLBA-01 PEMBROLIZUMAB (PEMBRO) VS PLACEBO AS POST NEPHRECTOMY ADJUVANT THERAPY FOR PATIENTS (pts) WITH RENAL CELL CARCINOMA (RCC): RANDOMIZED, DOUBLE-BLIND, PHASE 3 KEYNOTE-564 STUDY (2021) (0)
- Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers (2019) (0)
- PD67-04 ARE ACCOUNTABLE CARE ORGANIZATIONS ASSOCIATED WITH REDUCED EXPENDITURES FOR MEN WITH PROSTATE CANCER? (2019) (0)
- Abstract 1306: Biomarker results from a clinical trial of nivolumab in patients (pts) with metastatic renal cell carcinoma (mRCC) (CA209-009): Gene expression, serum profiling for immune markers, and multiplex tissue immunohistochemistry (IHC) (2015) (0)
- PD58-03 OPIOID PRESCRIPTIONS AFTER ROBOTIC VS. OPEN UROLOGIC PROCEDURES (2019) (0)
- 1482PDQTC INTERVAL PROLONGATION WITH VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS: A SYSTEMATIC REVIEW AND META-ANALYSIS. (2014) (0)
- Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy (2017) (0)
- Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer (2018) (0)
- Phase 2 study of pembrolizumab in patients with bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer: KEYNOTE-057 (2018) (0)
This paper list is powered by the following services:
Other Resources About Toni Choueiri
What Schools Are Affiliated With Toni Choueiri?
Toni Choueiri is affiliated with the following schools:
- Queen Mary University of London
- Karolinska Institute
- University of Texas Southwestern Medical Center
- Harvard University
- University of Western Ontario
- University of Calgary
- Pontifical Catholic University of Rio Grande do Sul
- MD Anderson Cancer Center
- University of Toronto
- Yonsei University
- Duke University
- Aarhus University
- Yale University
- Paris-Saclay University
- Sungkyunkwan University
- Vita-Salute San Raffaele University
